Allan M. Green
Boston College
4 Papers
26 Citations
Allan M. Green is an academic researcher from Boston College. The author has contributed to research in topics: Dementia & Observational study. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Aducanumab and the FDA - where are we now?
Howard Fillit,Allan M. Green +1 more
TL;DR: The amyloid antibody aducanumab is currently undergoing review by the FDA and is the first disease-modifying drug to be approved for Alzheimer's disease as discussed by the authors.
86
A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline
Penny A. Dacks,Joshua J. Armstrong,Stephen Brannan,Aaron J. Carman,Allan M. Green,M. Sue Kirkman,Lawrence R. Krakoff,Lewis H. Kuller,Lenore J. Launer,Simon Lovestone,Elizabeth Merikle,Peter J. Neumann,Kenneth Rockwood,Kenneth Rockwood,Diana W Shineman,Richard G. Stefanacci,Priscilla Velentgas,Anand Viswanathan,Rachel A. Whitmer,Jeff D. Williamson,Howard Fillit +20 more
TL;DR: The Alzheimer’s Drug Discovery Foundation convened an advisory panel to discuss the existing evidence and to recommend strategies to accelerate the development of comparative effectiveness research on how choices in the clinical care of common chronic diseases may protect from cognitive decline and dementia.
Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-making
Penny A. Dacks,Sandrine Andrieu,Deborah Blacker,Aaron J. Carman,Allan M. Green,Francine Grodstein,Victor W. Henderson,Bryan D. James,Rachel F Lane,Joseph Lau,Pei-Jung Lin,Barnaby C Reeves,Raj C. Shah,Bruno Vellas,Kristine Yaffe,Karin Yurko-Mauro,Diana W Shineman,David A. Bennett,Howard Fillit +18 more
- 01 Feb 2014
TL;DR: Informed decision-making by the general public on low-risk health choices that could have broad potential benefits could be enabled by internet-based tools and decision-aids to communicate the evidence, its quality, and the estimated magnitude of effect.
15
Overcoming obstacles to repurposing for neurodegenerative disease
Diana W Shineman,John Alam,Margaret Anderson,Sandra E. Black,Aaron J. Carman,Jeffrey L. Cummings,Penny A. Dacks,Joel T. Dudley,Donald E. Frail,Allan M. Green,Rachel F Lane,Debra Lappin,Tatyana Simuni,Richard G. Stefanacci,Todd Sherer,Howard Fillit +15 more
TL;DR: Opportunities on how philanthropy, industry, and government can begin to address challenges, promote policy changes, and develop targeted funding strategies to accelerate the potential of FDA‐approved repurposed drugs are presented.